glp-1 drug news Fmr. FDA Commissioner weighs in on Medicare's involvement in prices January 2026: New or Expanded

Although these mechanisms have been exploited to facilitate weight loss, these medications have also been indicated for patients with cardiovascular or renal diseases, all of which have caused a recent drastic rise in prescribing GLP-1 RAs

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

This update elevates obesity within the global noncommunicable disease agenda and sets a clear mandate for action

Discover how to access GLP-1 drugs like Wegovy & Ozempic without breaking the bank

Read more about the new GLP-1 pill that outperformed oral semaglutide in a recent Phase III trial.

While some ingredients show limited potential, the evidence remains nuanced and should be interpreted carefully